:
For each medication cohort, the use of other drugs of interest (i.e., SGLT2i, ACEi/ARB, GLP-1 RA, steroidal MRA [sMRA]) relative to the index medication was classified into three distinct time periods relative to the index date: within 90 days before, on, and within 90 days after, respectively
Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC
This sufficiently powered clinical study did not find a beneficial effect of linagliptin versus placebo on albuminuria in patients with T2DM, although exploratory analyses indicated more responders and fewer non-responders in terms of UACR in the linagliptin group